Payment overview · 2025
General Payments
$365.85
19 reported records · 11 companies
Healthcare provider profile · identity verified
Louis James Saddler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANTON, MS · NPI 1497765705
Verified facts
What the public records show
CMS Open Payments records show Louis James Saddler, MD received $365.85 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 446 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.53 | 20.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.31 | 10.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.39 | 10.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.95 | 10.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.82 | 10.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.77 | 10.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.57 | 8.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.05 | 5.8% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $17.42 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.84 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.20 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.85 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.53 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 251 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 446 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
251 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
446 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1333 | 203 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 653 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 642 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 152 |
| Potassium Chloride | Potassium Chloride | 491 | 134 |
| Ozempic | Semaglutide | 446 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 394 | 106 |
| Omeprazole | Omeprazole | 377 | 115 |
| Gabapentin | Gabapentin | 365 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 279 | 81 |
| Metformin Hcl | Metformin Hcl | 277 | 77 |
| Linzess | Linaclotide | 251 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 67 |
| Tramadol Hcl | Tramadol Hcl | 229 | 54 |
| Allopurinol | Allopurinol | 228 | 74 |
| Furosemide | Furosemide | 228 | 86 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 215 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 59 |
| Carvedilol | Carvedilol | 211 | 55 |
| Nifedipine Er | Nifedipine | 208 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 199 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 62 |
| Losartan Potassium | Losartan Potassium | 182 | 55 |
| Eliquis | Apixaban | 181 | 29 |
| Meloxicam | Meloxicam | 170 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 44 |
| Ibuprofen | Ibuprofen | 160 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 46 |
| Famotidine | Famotidine | 154 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 44 |
| Mounjaro | Tirzepatide | 145 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 135 | 37 |
| Fluconazole | Fluconazole | 131 | 46 |
| Prednisone | Prednisone | 131 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 41 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 122 | 35 |
| Lisinopril | Lisinopril | 118 | 35 |
| Spironolactone | Spironolactone | 115 | 30 |
| Pregabalin | Pregabalin | 114 | 29 |
| Jardiance | Empagliflozin | 108 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 19 |
| Metformin Hcl Er | Metformin Hcl | 100 | 34 |
| Januvia | Sitagliptin Phosphate | 98 | 21 |
| Alprazolam | Alprazolam | 97 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 15 |
| Chlorthalidone | Chlorthalidone | 94 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 42 |
| Entresto | Sacubitril/Valsartan | 93 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 22 |
| Naproxen | Naproxen | 89 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 25 |
| Lorazepam | Lorazepam | 86 | 18 |
| Azithromycin | Azithromycin | 85 | 67 |
| Rybelsus | Semaglutide | 85 | 19 |
| Glipizide | Glipizide | 83 | 26 |
| Colchicine | Colchicine | 82 | 26 |
| Meclizine Hcl | Meclizine Hcl | 82 | 24 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Amoxicillin | Amoxicillin | 80 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 20 |
| Promethazine Hcl | Promethazine Hcl | 75 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 75 | 13 |
| Ondansetron Odt | Ondansetron | 74 | 16 |
| Clonidine Hcl | Clonidine Hcl | 73 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 73 | 13 |
| Simvastatin | Simvastatin | 72 | 23 |
| Trazodone Hcl | Trazodone Hcl | 71 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 22 |
| Buspirone Hcl | Buspirone Hcl | 69 | 13 |
| Mupirocin | Mupirocin | 69 | 37 |
| Trulicity | Dulaglutide | 68 | 12 |
| Verapamil Er | Verapamil Hcl | 67 | 19 |
| Synjardy | Empagliflozin/Metformin Hcl | 63 | 13 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Clonazepam | Clonazepam | 59 | 13 |
| Novolog Flexpen | Insulin Aspart | 59 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 17 |
| Xolair | Omalizumab | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 39 |
| Baclofen | Baclofen | 51 | suppressed |
| Levetiracetam | Levetiracetam | 50 | 13 |
| Myrbetriq | Mirabegron | 48 | 12 |
| Nystatin | Nystatin | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 14 |
| Dutasteride | Dutasteride | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Valsartan | Valsartan | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 42 | 33 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 41 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 21 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 38 | 12 |
| Methylprednisolone | Methylprednisolone | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | 11 |
| Ibu | Ibuprofen | 33 | 13 |
| Cephalexin | Cephalexin | 30 | 23 |
| Indomethacin | Indomethacin | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 20 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 12 |
| Estradiol | Estradiol | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Erythromycin-Benzoyl Peroxide | Erythromycin/Benzoyl Peroxide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.85 · 19 records | Amgen Inc. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, DUPIXENT, GEMTESA, JARDIANCE, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, VOQUEZNA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error